Skip to content

Dianthus Therapeutics, Inc.

DNTH· NasdaqCore metricsCIK 1690585

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · +3.74%
Market cap
$5.21B
56.31M shares
Filings
661
$2.04M
FY 2025−67.3% FY25 yoy
-$46.64M
Q3 2026N/M FY25 yoy
-$58.47M
Q3 2026N/M FY25 yoy
-$15.26M
Q2 2023derivedN/M FY22 yoy
-$0.81
Q3 2026N/M FY25 yoy
$55.69M
Q3 2026+124.1% FY25 yoy
$5.21B
—
2559.2×
4.2×
—
—

FY2025 figures · derived

Price

$92.53+156.32%+$56.43past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.04MFY 2025
$6.24M0FY 2016FY 2017FY 2018FY 2019FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,036,000reported
FY 20242024-12-31$6,235,000reported
FY 20232023-12-31$2,826,000reported
FY 20192019-12-31$0reported
FY 20182018-12-31$0reported
FY 20172017-12-31$0reported
FY 20162016-12-31$0reported

Pharmaceutical preparations

Dianthus Therapeutics, Inc. is the 201st largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Dianthus Therapeutics, Inc. · CIK 1690585 · Engraved from SEC EDGAR